Associate Editor, Ophthalmology Times
ARVO LIVE: EU update on EyeArt with Eyenuk CEO and founder
Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.
ARVO LIVE: Epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells
Ophthalmology Times® talked with Bruce Ksander, PhD, about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells at this year's ARVO meeting.
ARVO LIVE: Monkeypox eye disease in the immunocompromised
Ophthalmology Times® talked with Steven Carrubba, MD, about monkeypox skin disease and eye disease in patients who were immunocompromised in New York at this year's ARVO meeting.
ARVO LIVE: OTT166 in the treatment of diabetic retinopathy
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
ARVO LIVE: Treatment of GUCY2D associated Leber congenital amaurosis type 1
Ophthalmology Times® talked with Christine Kay, MD, about the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting.
ARVO LIVE: ARMOR study and antibiotic resistance
Ophthalmology Times® talked with Penny Asbell, MD, FACS, MBA, about the ARMOR study and antibiotic resistance at this year's ARVO meeting.
ARVO LIVE: Lamina cribrosa pressure and predicting structural glaucoma progression
Ophthalmology Times® talked with Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.
ARVO LIVE: YOSEMITE and RHINE trials comparing faricimab to aflibercept
Ophthalmology Times® talked with Roger Goldberg, MD, MBA, about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept at this year's ARVO meeting.
ARVO LIVE: Early detection of diabetic retinopathy in underserved communities
Ophthalmology Times® talked with Edmund Arthur, OD, PhD, FAAO, about his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.
ARVO LIVE: Ascidian Therapeutics' research into gene therapy
Ophthalmology Times® talked with Jay Barth, MD, about the work at Ascidian Therapeutics and their research into developing a new way to administer gene therapy at this year's ARVO meeting.
ARVO LIVE: Trefoil Therapeutics CEO gives update on TTHX1114 in patients with FECD
Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.
ARVO 2023: Capillary density as a biomarker for the assessment of cognitive impairment in Alzheimer's Disease
Amir H. Kashani, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.
ARVO LIVE: Myopia progression with low-concentration atropine
Ophthalmology Times® talked with Mark Bullimore and discussed the control of myopia progression with low-concentration atropine from the Hong-Kong LAMP study at this year's ARVO meeting.
ARVO LIVE: Predictive AI algorithms and data interpretation
Ophthalmology Times® talked with T. Y. Alvin Liu, MD, about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.
ARVO 2023: Retinal engineering and RGC replacement
Thomas V. Johnson, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on retinal engineering and RGC replacement.
ARVO LIVE: Visual function, imaging and artificial intelligence with Apellis
Ophthalmology Times® talked with Caroline Baumal, MD, about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.
ARVO LIVE: Analysis of vision loss from GATHER clinical program
Ophthalmology Times® talked with Carl Danzig, MD, FASRS, at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.
ARVO LIVE: Insight into cell death with AMD
Ophthalmology Times® talked with Deborah Ferrington, PhD, about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.
ARVO LIVE: eSight Go: Smart glasses for low vision enhancement
Ophthalmology Times® talked with Roland Mattern, Director of Sales and Marketing for eSight and eSight User Gary Foster at this year's ARVO meeting about eSight Go, the new model of smart glasses for low vision enhancement
ARVO LIVE: Lexitas modified National Eye Institute scale
Ophthalmology Times® talked with George Magrath, MD, and Andrew Pucker, OD, MS, PhD, FAAO at this year's ARVO meeting about Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.
Nova Eye Medical announces FDA clearance in the US market for iTrack Advance
The device is an update on the previous iTrack canaloplasty device and features an ergonomic handpiece.
Aviceda announces FDA clearance of IND application for AVD-104
The clearance of the Investigational New Drug Application will allow the company to initiate Phase 2 trials of the drug for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Bausch + Lomb partners with Heidelberg Engineering to introduce SeeLuma
SeeLuma is a “Fully Digital Surgical Visualization Platform” to assist ophthalmic surgeons.
Ocular surface disease and lifestyle choices that affect eye health
Esen Akpek, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss ocular surface disease and the lifestyle choices that could affect eye health. As well as what The Tear Film & Ocular Surface Society is doing to promote research on the topic.
Retina & Vitreous of Texas, PLLC informs patients of data security breach
Patients and employees, past and present, have had personal and protected health information acquired without authorization.
FDA inspection finds dozens of contamination issues at recalled eye drop manufacturer’s facility
Dirty equipment and sterilization issues are among the many violations found by the FDA.
Prevent Blindness designates April as women’s eye health and safety month
The month will serve to educate the public on a variety of women’s vision issues.
Alembic pharmaceuticals announces USFDA Final Approval for brimonidine tartrate ophthalmic solution 0.15%.
Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma.
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101
GAL-101 is a Phase 2/3-ready small molecule used to treat ophthalmic indications with high unmet medical need.
COPHy 2023: Debating the value of home monitoring as a management option for AMD
The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal
2 Clarke Drive Cranbury, NJ 08512